N,N-dimethyl-4-(pyrimidin-2-yl)piperazine-1-sulfonamide | 99191-22-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N,N-dimethyl-4-(pyrimidin-2-yl)piperazine-1-sulfonamide
• 英文别名: 4-pyrimidin-2-yl-piperazine-1-sulfonic acid dimethylamide；4-Pyrimidin-2-yl-piperazin-1-sulfonsaeure-dimethylamid；1-N,N-dimethylsulfamoyl-4-(2-pyrimidinyl)piperazine；1-N,N'-dimethylsulfamoyl-4-(2-pyrimidyl)piperazine；N,N-dimethyl-4-pyrimidin-2-ylpiperazine-1-sulfonamide
• CAS: 99191-22-7
• 化学式: C₁₀H₁₇N₅O₂S
• 分子量: 271.343
• InChiKey: IMNYTTPYTYHSJH-UHFFFAOYSA-N

物化性质

• 熔点：
  157-158 °C
• 沸点：
  464.3±48.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-氯嘧啶 、 N,N-二甲基-1-哌嗪磺酰胺 生成 N,N-dimethyl-4-(pyrimidin-2-yl)piperazine-1-sulfonamide
  参考文献：
  名称：

  Multifunctional Compounds and Methods of Use Thereof

  摘要：

  提供了包含多功能剂的组合物和使用方法。

  公开号：

  US20090105269A1

文献信息

• Anti-cataract agent
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP0806422A2

  公开（公告）日：1997-11-12

  Compounds represented by the general Formula (I); wherein A represents a pyrimidine ring, R1 and R2 represent independently hydrogen or optionally substituted C1-6 alkyl or alkoxy and salts thereof are effective for preventing or treating cataract by oral or parenteral administration. The pyrimidine ring can be attached to the piperazine ring at a carbon or nitrogen atom of the piperazine ring.

  通式（I）所代表的化合物；其中A代表嘧啶环，R1和R2分别代表氢或可选取代的C1-6烷基或烷氧基，以及其盐，可以通过口服或静脉注射有效地预防或治疗白内障。嘧啶环可以连接到哌嗪环的一个碳或氮原子上。
• 1-substituted-4-sulfamylpiperazine and method of preparing the same
  申请人：AMERICAN CYANAMID CO

  公开号：US02748125A1

  公开（公告）日：1956-05-29
• Multifunctional Antioxidants for the Treatment of Age-Related Diseases
  作者：Hongxia Jin、James Randazzo、Peng Zhang、Peter F. Kador

  DOI：10.1021/jm901381j

  日期：2010.2.11

  Analogues of N,N-dimethyl-4-(pyrimidin-2-yl)piperazine-l-sulfonamide possessing a free radical scavenger group (FRS), chelating groups (CHL), or both (FRS + CHL) have been synthesized. Electrospray ionization mass spectrometry studies indicate that select members of this series bind ions in the relative order of Cu1+ = Cu2+ >Fe2+ = Fe3+ > Zn2+ with no binding of Ca2+ or Mg2+ observed. In vitro evaluation of these compounds in human lens epithelial, human retinal pigmented epithelial, and human hippocampal astrocyte cell lines indicates that all analogues possessing the FRS group as well as the water-soluble vitamin E analogue 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid protect these cells against decreased cell viability and glutathione levels induced by hydrogen peroxide. In addition, those compounds possessing CHL groups also protected these cells against hydroxyl radicals generated by the Fenton reaction. These compounds are good candidates for the preventive treatment of cataract, age-related macular degeneration (AMD), and Alzheimer's dementia (AD).